Per 31 December 2019, Jochem Bossenbroek resigns as CEO of BunyaVax. He has been CEO since September 2017. Carine Punt has been appointed...

On 29-30 September, the first Animal AgTech Innovation Summit was held in Amsterdam. The summit brought together 200 international leader...

BunyaVax provides technology to develop a human Rift Valley Fever vaccine in a $12.5 million project financed by CEPI BunyaVax is technol...

On the 17th of January 2019, Jochem will be one of the speakers at the live webinar Investment Trends in Animal Health. The webinar is or...

On Thursday 27 September StartupDelta announced their overview of 10 Dutch Breakthrough Technologies for 2018. BunyaVax made it to the li...

Jochem Bossenbroek, CEO of BunyaVax, has accepted the invitation to join a panel discussion at the World Agri-Tech Innovation Summit. The...

Jeroen Kortekaas, CSO of BunyaVax, is invited as session speaker at the Immuno Valley Annual Conference 2018. The event will take place i...

The journal Wageningen World has published an article about BunyaVax in the second edition of 2018: "Vaccines within months instead of ye...

BunyaVax receives 50.000 euro from the European Commission (EC). The funding proposal of BunyaVax was selected out of hundreds of applica...

Last week BunyaVax has won the 2018 Innovation Showcase Award at Animal Health Investment Europe. The event, organized by Kisaco Research...

BunyaVax will present at the Animal Health Investment Summit in Londen that will take place on 20-21 Februari 2018. BunyaVax is one of th...

BunyaVax has been awarded €40k under the NWO Take-off programme. The grant allows BunyaVax to determine the route to market for its swine...

BunyaVax has appointed Jochem Bossenbroek MSc. MBA as CEO of the company. Jochem has extensive experience in the biotech sector, gained t...

Prof. Jeroen Kortekaas PhD, CSO of BunyaVax, and Paul Wichgers Schreur PhD, COO of the company, share their vision on the future of Bunya...

Today, the biotech company BunyaVax B.V. was officially launched. Goal of the company is to commercialize novel proprietary vaccine platf...